These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 1776388

  • 1. Selegiline and cognitive function in Parkinson's disease.
    Hietanen MH.
    Acta Neurol Scand; 1991 Nov; 84(5):407-10. PubMed ID: 1776388
    [Abstract] [Full Text] [Related]

  • 2. Selegiline hydrochloride and cognition.
    Lees AJ.
    Acta Neurol Scand Suppl; 1991 Nov; 136():91-4. PubMed ID: 1801544
    [Abstract] [Full Text] [Related]

  • 3. Effect of selegiline on cognitive functions in Parkinson's disease.
    Dixit SN, Behari M, Ahuja GK.
    J Assoc Physicians India; 1999 Aug; 47(8):784-6. PubMed ID: 10778622
    [Abstract] [Full Text] [Related]

  • 4. Effects of selegiline (deprenyl) on cognition in early Parkinson's disease.
    Dalrymple-Alford JC, Jamieson CF, Donaldson IM.
    Clin Neuropharmacol; 1995 Aug; 18(4):348-59. PubMed ID: 8665548
    [Abstract] [Full Text] [Related]

  • 5. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P, Teräväinen H.
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Selegiline as a primary treatment of Parkinson's disease.
    Myllylä VV, Sotaniemi KA, Vuorinen JA, Heinonen EH.
    Acta Neurol Scand Suppl; 1991 Jul; 136():70-2. PubMed ID: 1801540
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease. A double-blind crossover trial.
    Presthus J, Berstad J, Lien K.
    Acta Neurol Scand; 1987 Sep; 76(3):200-3. PubMed ID: 3120487
    [Abstract] [Full Text] [Related]

  • 12. The relationship between depression and regional cerebral blood flow in Parkinson's disease and the effect of selegiline treatment.
    Imamura K, Okayasu N, Nagatsu T.
    Acta Neurol Scand; 2011 Jul; 124(1):28-39. PubMed ID: 20880269
    [Abstract] [Full Text] [Related]

  • 13. Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study.
    Sacktor N, Schifitto G, McDermott MP, Marder K, McArthur JC, Kieburtz K.
    Neurology; 2000 Jan 11; 54(1):233-5. PubMed ID: 10636157
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Selegiline (L-deprenyl) and L-dopa treatment of Parkinson's disease: a double-blind trial.
    Takahashi M, Yuasa R, Imai T, Tachibana H, Yorifuji S, Nakamura Y, Ogawa N.
    Intern Med; 1994 Sep 11; 33(9):517-24. PubMed ID: 8000101
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study.
    Cereda E, Cilia R, Canesi M, Tesei S, Mariani CB, Zecchinelli AL, Pezzoli G.
    J Neurol; 2017 Jun 11; 264(6):1254-1263. PubMed ID: 28550482
    [Abstract] [Full Text] [Related]

  • 20. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group.
    Pålhagen S, Heinonen EH, Hägglund J, Kaugesaar T, Kontants H, Mäki-Ikola O, Palm R, Turunen J.
    Neurology; 1998 Aug 11; 51(2):520-5. PubMed ID: 9710028
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.